Clinical Trials

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

198 enrolled

Carcinoma, Hepatocellular

NCT07466225 2026-03-12

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Not yet recruiting

150 enrolled

Carcinoma, Hepatocellular

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Cholangiocarcinoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Phase NA Not yet recruiting

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

1,000 enrolled

Carcinoma, Hepatocellular

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Carcinoma, Hepatocellular

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

36 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

29 enrolled

BTC

NCT07160361 2025-09-16

Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

56 enrolled

Carcinoma, Hepatocellular

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

48 enrolled

Phase NA Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

74 enrolled

Biliary Tract Neoplasms

NCT06884982 2025-03-19

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Carcinoma, Hepatocellular

NCT06849492 2025-02-27

SHIFT-001

120 enrolled

Breast

Advanced Triple Negative Breast Cancer

NCT06748508 2024-12-27

FDZL-GC003

141 enrolled

Phase 1/2 Not yet recruiting

Stomach Neoplasms

NCT06746961 2024-12-24

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

49 enrolled

Esophageal Squamous Cell Carcinoma

NCT06648525 2024-10-18

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

68 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06563934 2024-08-21

Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)

70 enrolled

Liver Neoplasms

NCT06499610 2024-07-12

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT06417606 2024-05-22

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

20 enrolled

Phase 1/2 Not yet recruiting

Cholangiocarcinoma

NCT06409637 2024-05-10

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

62 enrolled

Liver Neoplasms

NCT06389500 2024-04-29

HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

NCT06253598 2024-03-07

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

58 enrolled

Breast

Breast Neoplasms

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Phase 3 Not yet recruiting

104 enrolled

Carcinoma, Hepatocellular

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients